Drug Trial Radar · NCT05083169
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
587
Actual
Start
Oct 14, 2021
Primary completion
Aug 1, 2025
Study completion Sep 15, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
Conditions
- Multiple Myeloma
Interventions
DaratumumabDrug
Daratumumab will be administered SC injection.
PomalidomideDrug
Pomalidomide will be administered orally.
DexamethasoneDrug
Dexamethasone will be administered orally or intravenously.
BortezomibDrug
Bortezomib will be administered SC injection.
TeclistamabDrug
Teclistamab will be administered SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to 5 years
Locations
176 sites in 21 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
City of Hope
Duarte, California
Stanford University Medical Center
Stanford, California
Yale University
New Haven, Connecticut
Emory University Winship Cancer Institute
Atlanta, Georgia
Tufts Medical Center
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Henry Ford Health System
Southfield, Michigan
Cleveland Clinic
Cleveland, Ohio
West Penn Hospital
Pittsburgh, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Baptist Cancer Center
Memphis, Tennessee
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Fred Hutchinson Cancer Center
Seattle, Washington
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Hospital Aleman
CABA, Argentina
Hospital Privado Centro Medico de Cordoba
Córdoba, Argentina
ZAS Cadix
Antwerp, Belgium
AZ St.-Jan Brugge-Oostende AV
Bruges, Belgium
UZ Gent
Ghent, Belgium
Hopital de Jolimont
Haine Saint Paul La Louviere, Belgium
Az Groeninge
Kortrijk, Belgium
UZ Leuven
Leuven, Belgium
Algemeen Ziekenhuis Delta
Roeselare, Belgium
Hospitais Integradaos da Gavea S/A - DF Star
Brasília, Brazil
Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
Curitiba, Brazil
Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN
Florianópolis, Brazil
Liga Norte Riograndense Contra O Cancer
Natal, Brazil
Irmandade Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
Rio de Janeiro, Brazil
IDOR - Regional Bahia
Salvador, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia
São Paulo, Brazil
Hospital Paulistano
São Paulo, Brazil
Clinica Medica Sao Germano LTDA
São Paulo, Brazil
Instituto D Or de Pesquisa e Ensino IDOR
São Paulo, Brazil
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.